VEXAS综合征治疗结局:异基因造血干细胞移植与去甲基化药物的多中心对比队列研究
该多中心回顾性研究纳入66例VEXAS综合征患者,比较异基因造血干细胞移植(alloHSCT,n=31)与去甲基化药物(HMA,n=35)的治疗结局。alloHSCT组全部可评估患者达分子学缓解,58%停用糖皮质激素;HMA组分子学缓解率22%、停药率6%。多因素分析显示alloHSCT与总生存改善相关(HR=0.20,95%CI:0.05-0.81;p=0.024)。
要点
- alloHSCT组可评估患者均达分子学缓解,58%停用糖皮质激素。
- HMA组分子学缓解率22%、停用糖皮质激素率6%,因毒性或无效停药率高。
- 校正年龄和Charlson共病指数后,alloHSCT与总生存改善相关(HR=0.20)。
核心结论
- 在选择的VEXAS患者中,alloHSCT仍是具有吸引力且可能治愈的策略。
- HMA治疗虽可诱导部分缓解,但分子学缓解率和激素停用率较低。
研究设计与样本
- 多中心回顾性对比队列研究,纳入66例VEXAS综合征患者。
- 患者接受HMA(n=35)或alloHSCT(n=31)治疗。
- 两组基线特征(遗传学、共病、体能状态)均衡,但HMA组年龄更大。
- 中位随访时间自治疗开始为18个月(95%CI:11-26)。
主要发现
- 共报告14例(21%)死亡,其中alloHSCT组3例,HMA组11例。
- alloHSCT组全部可评估患者达分子学缓解,58%停用糖皮质激素。
- HMA组分子学缓解率22%,停用糖皮质激素率6%。
- HMA治疗因毒性或缺乏反应而停药率高。
- 多因素分析校正年龄和Charlson共病指数后,alloHSCT与总生存改善相关(HR=0.20,95%CI:0.05-0.81;p=0.024)。
临床怎么用
- 对于选择的VEXAS患者,alloHSCT可考虑作为可能治愈的策略。
- HMA治疗需注意因毒性或无效导致的高停药率。
局限性
- 研究为回顾性设计,存在固有局限性。
- 结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics such as genetics, co-morbidities, and performance status were balanced between the groups, except older age in the HMA group. Median follow-up from therapy initiation was 18 months (95% CI: 11-26), and 14 (21%) deaths were reported (alloHSCT n = 3; HMA n = 11). Among all evaluable patients within the alloHSCT cohort, all patients achieved molecular remission, and a substantial proportion of patients discontinued glucocorticoids (58%). In contrast, HMA therapy was associated with lower but meaningful rates of molecular remission (22%) and glucocorticoid discontinuation (6%). In a real-world setting, HMA therapy was associated with a high discontinuation rate related to toxicity or lack of response. On multivariable analysis adjusted for age and Charlson Comorbidity Index, alloHSCT was associated with improved overall survival (HR = 0.20, 95% CI: 0.05-0.81; p = 0.024). This association remained consistent across multiple ancillary sensitivity analyses, including restriction to transplant-eligible patients, patients aged ≤ 75 years, 1:1 matching, and propensity score-based weighted analyses. Although limited by retrospective design, these findings suggest that alloHSCT remains an attractive and potentially curative strategy in selected patients with VEXAS. Prospective validation of these findings is warranted.
引用
- Fathima S, Wong MM, Gonzalez-Lugo J, et al. Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents. Am J Hematol. 2026. PMID: 42260942. doi:10.1002/ajh.70401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。